Author: Business Wire

Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release first quarter 2018 financial results after the market close on Wednesday, May 9, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 9,

Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018. The studies examined the use of OMIDRIA in both routine and complex cataract surgery cases perf

Ophthalmology Pipeline Database 2018: Conjunctivitis, Glaucoma, Diabetic Retinopathy, Myasthenia Gravis, Dry Eye Syndrome, Age-related Macular Degeneration, and Cataract – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Pipeline Database – 2018” report has been added to ResearchAndMarkets.com’s offering. Ophthalmology Pipeline Highlights Database – 2018, provides most up-to-date information on key pipeline products in the gl…

Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29th – May 3rd, 2018, in Honolulu, Hawaii. The scheduled times (noted in local Hawaii time) and location of the BioTime data presen

SERI Lugano: la FDA selecciona la riboflavina ParaCel para su uso como parte del protocolo de reticulación sin extirpación del epitelio para el tratamiento del queratocono

LUGANO, Suiza–(BUSINESS WIRE)–El Switzerland Eye Research Institute ha anunciado que la innovadora formulación de la riboflavina transepitelial, conocida como ParaCel, basada en la investigación de su CEO y fundador, Roberto Pinelli, MD, ha sido seleccionada entre muchas otras formulaciones por la FDA (Administración de Alimentos y Fármacos de EE. UU.) para un protocolo de reticulación (cross-linking, CXL) de colágeno corneal sin extirpación del epitelio (epi-on) en pacientes que padecen quer

SERI Lugano: la FDA selecciona la riboflavina ParaCel para su uso como parte del protocolo de reticulación sin extirpación del epitelio para el tratamiento del queratocono

LUGANO, Suiza–(BUSINESS WIRE)–El Switzerland Eye Research Institute ha anunciado que la innovadora formulación de la riboflavina transepitelial, conocida como ParaCel, basada en la investigación de su CEO y fundador, Roberto Pinelli, MD, ha sido seleccionada entre muchas otras formulaciones por la FDA (Administración de Alimentos y Fármacos de EE. UU.) para un protocolo de reticulación (cross-linking, CXL) de colágeno corneal sin extirpación del epitelio (epi-on) en pacientes que padecen quer

IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery

SAN CLEMENTE, Calif. & WASHINGTON–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent inject® Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocul

Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has filed a patent infringement lawsuit against Ivantis, Inc. in the U.S. District Court for the Central District of California, Southern Division. The lawsuit alleges that Ivantis’ Hydrus Microstent device infringes Glauko